The bill adds a new federal offense to chapter 74 of Title 18 (retitling the chapter header to “ABORTION CRIMES”) that targets provision or attempted provision of abortion via chemical abortion drugs when three conditions are met: the patient was not physically examined, the clinician was not physically present at the location of the abortion, and the provider did not supply a "catch kit" and red-bag medical waste for return to the clinician. Conviction carries up to 5 years imprisonment, a fine up to $50,000 per occurrence, or both.
This is a statutory attempt to foreclose remote medication abortion delivery and mail-order distribution by creating a federal criminal prohibition tied to interstate commerce. The text defines terms broadly (sweeping in mifepristone, misoprostol, and future drugs) and includes precise packaging/disposal requirements.
The drafting choices — conjunctive offense elements, a narrow set of medical exceptions, and an unusual waste-return mandate — create a mix of enforcement pathways and practical ambiguities that will matter to telemedicine providers, pharmacies, clinics, waste handlers, and federal prosecutors.
At a Glance
What It Does
The bill creates Section 1532 in Title 18 making it a federal crime to provide a chemical abortion when the clinician did not physically examine the patient, was not physically present at the place the medication was used, and failed to provide a catch kit and red-bag medical waste for return. It names specific drugs and gives the statute explicit definitions for terms such as "chemical abortion drug," "catch kit," and "red bag medical waste."
Who It Affects
Telemedicine platforms that prescribe or facilitate medication abortion, pharmacies that ship mifepristone or misoprostol, clinics that support at-home dosing, manufacturers and distributors of abortion medications, and federal and state law enforcement charged with investigating interstate mail or telehealth activity.
Why It Matters
The statute imports criminal penalties into an area largely governed by medical licensing and FDA regulation, extends federal reach via the 'in or affecting interstate commerce' hook, and ties culpability to specific, operational details (physical presence, examination, disposal logistics) that will drive compliance costs and enforcement choices.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill revises chapter 74 of Title 18 by changing its header to 'ABORTION CRIMES' and inserting a new section (1532) that targets provision of chemical abortion drugs outside an in-person medical context. It frames the prohibited conduct as providing or attempting to provide abortion through a chemical abortion drug while simultaneously meeting three conditions: no physical examination of the patient, no physical presence of the clinician at the location where the drug is used, and failure to provide a 'catch kit' and 'red bag' medical waste container with instructions to return it to the clinician.
The statute defines key terms tightly. 'Chemical abortion drug' expressly lists mifepristone and misoprostol and includes substantially similar generics and any drug marketed for the purpose of causing abortion. 'Catch kit' and 'red bag medical waste' are defined with labeling and color requirements. The bill also provides a definition of 'unborn child' from fertilization until live birth and lists narrow exceptions (for saving or preserving the health of the unborn child, removal of a dead unborn child after spontaneous abortion, and ectopic pregnancies).Criminal exposure is tied to federal jurisdiction: the prohibited acts must be 'in or affecting interstate commerce,' which is the vehicle for applying Title 18 to mail-order and telemedicine scenarios.
Whoever violates the provision faces imprisonment of up to five years and a monetary fine up to $50,000 for each occurrence. Finally, the bill makes a clerical change to the chapter table of sections to add the new offense.
The Five Things You Need to Know
The statute requires three conditions all to be present for criminal liability: (1) no physical examination, (2) the provider not physically present at the abortion location, and (3) no provision of a catch kit and red-bag medical waste — the elements are written conjunctively.
Penalties are set at up to 5 years in prison and a fine up to $50,000 per occurrence, enabling multiple charges/fines for multiple doses or multiple patients.
The offense applies to conduct 'in or affecting interstate commerce,' explicitly bringing mail-order shipments and cross-state telemedicine within federal reach.
The definition of 'chemical abortion drug' specifically lists mifepristone and misoprostol and also covers 'any drug developed, marketed, sold, or distributed for the purpose of causing an abortion,' which captures future products and off-label uses tied to abortion.
The bill mandates a particular disposal protocol: a labeled 'red bag' medical waste container and a 'catch kit'—with a statutory requirement that the patient be instructed to bring those items back to the healthcare provider for disposal.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Establishes the Act’s short title as the 'Clean Water for All Life Act.' This is purely nominal but signals the bill’s focus; it does not affect substance or legal interpretation of the operative provisions.
Chapter header revision
Replaces the current chapter header 'PARTIAL-BIRTH ABORTIONS' with 'ABORTION CRIMES.' The change is clerical but reframes the chapter to encompass broader abortion-related offenses and sets up insertion of the new criminal provision.
Creates the substantive federal offense
Adds Section 1532 which makes it a federal crime to provide or attempt to provide a chemical abortion drug under a three-part test: absence of a physical exam of the patient, absence of the provider at the location where the medication is used, and failure to provide specified waste-containment materials. The provision is explicit that liability attaches 'in or affecting interstate commerce,' which is the statutory basis for federal jurisdiction over telemedicine and mail-delivered medications.
Detailed definitions for scope and application
The text defines 'abortion' (with narrow exceptions), 'chemical abortion drug' (listing mifepristone and misoprostol and capturing similar future drugs), 'catch kit,' 'red bag medical waste,' 'fertilization,' and 'unborn child.' Those definitions fix statutory reach and operationalize enforcement (for example, by specifying labeling/color requirements for red-bag waste), but they also introduce drafting quirks—most notably the phrasing of the medical exceptions—which will shape judicial interpretation.
Clerical table of sections amendment
Adds the new Section 1532 to the chapter’s table of sections. This is the mechanical step that integrates the new offense into Title 18’s indexing and accessible structure.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- In-person clinics and practitioners who already provide on-site medication abortion: reduced competition from remote providers and mail-order services may increase patient volume for those offering supervised, in-person care.
- Manufacturers and vendors of medical waste containment products and disposal services: the statutory requirement for catch kits and red-bag waste creates a definable commercial need for compliant containers and collection services.
- Federal prosecutors and law enforcement agencies seeking clearer statutory language to charge cross-border medication-abortion facilitation: the 'in or affecting interstate commerce' language and enumerated elements give prosecutors a tailored federal statute to use in investigations.
Who Bears the Cost
- Telemedicine platforms and remote clinicians that prescribe medication abortion: they face new criminal risk unless they redesign care pathways to assure in-person exams and physical presence, or avoid prescribing abortion drugs entirely.
- Pharmacies and mail-order distributors that ship mifepristone or misoprostol: they may need to halt interstate shipping, implement complex verification systems, or face exposure to federal criminal charges.
- Patients seeking at-home medication abortion: increased travel, time, expense, or inability to access medication if local providers or pharmacies decline to participate; patients may also confront requirements to transport biohazardous waste back to a clinician.
- Healthcare providers and clinics that try to comply: added administrative burdens (tracking returns of red-bag waste, supplying kits, documenting physical exams and presence) and potential malpractice or criminal exposure if documentation is challenged.
- Federal and state enforcement systems: the statute creates investigative workload and potential prosecution costs, and may spur interjurisdictional disputes about enforcement priorities and resource allocation.
Key Issues
The Core Tension
The central tension is between a criminal-law approach to constraining cross-border and remote use of medication abortion and traditional regulatory tools (medical licensing, FDA oversight, and state practice of medicine). The bill pursues preventing remote provision through criminal penalties and operational packaging requirements, but those same tools can undermine medically accepted telehealth practices, create enforcement and public-health complications, and raise hard questions about federal reach into clinical decisionmaking.
The bill raises several implementation and interpretive questions that are not resolved within the text. First, the offense is drafted conjunctively: all three listed conditions must be met for criminal liability.
That creates odd outcomes — a provider who prescribes remotely but supplies a catch kit might not fall within the statute, and a provider physically present but who did not perform a formal 'physical examination' could still avoid liability. The statute does not define what qualifies as a 'physical examination' or what it means to be 'physically present at the location of the chemical abortion,' leaving courts to decide whether presence in the same building, the same residence, or the same room is required.
Second, the waste-return mandate creates practical safety and public-health questions. Requiring patients to return biohazardous material to a clinician raises risks and logistical burdens; the bill does not address chain-of-custody, liability for contaminated deliveries, or whether postal or courier carriage of such returned waste is lawful.
Third, the medical exceptions are drafted unusually: the exemption protects acts performed to 'save the life or preserve the health of the unborn child,' language that appears to focus on fetal health rather than the pregnant person's health. That drafting could narrow the intended medical-necessity defense and produce ambiguity in emergent situations.
Finally, the statute locates federal authority in 'interstate commerce,' creating friction with existing FDA regulation and state medical-practice regimes. The interplay between criminal law, FDA approvals and labeling decisions, and state licensure standards is unresolved here: courts will need to confront whether federal criminalization intrudes on medical regulation, how to reconcile this law with FDA-authorized distribution channels for mifepristone, and whether state-level telemedicine permissive regimes create safe harbors or conflicts.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.